秋水仙碱预防和治疗心包炎的有效性及安全性的系统评价

Efficacy and Safety Evaluation of Colchicine for the Prevention and Treatment of Pericarditis:a Systematic Review

目的:系统评价秋水仙碱预防和治疗心包炎的有效性及安全性。方法:计算机检索OVID、EMbase、SCI、中国生物医学文献数据库(CBM)、中国知网全文数据库(CNKI)、维普中文期刊数据库(VIP)等数据库,纳入秋水仙碱预防及治疗心包炎的随机对照试验。系统筛选文献、提取资料及评价质量后,对同质研究采用RevMan5.0软件进行Meta分析。结果:共纳入5项研究,795例患者。Meta分析结果显示,试验组与对照组心包切开术后综合征(PPS)发生率[RR=0.44,95%CI(0.27,0.70),P=0.0006]或心包炎复发率[RR=0.42,95%C(I0.29,0.60),P<0.00001]差异均有统计学意义。2组不良反应发生率比较,差异无统计学意义[RR=1.22,95%CI(0.72,2.07),P=0.47]。结论:在常规治疗或联合阿司匹林治疗的基础上,联用秋水仙碱能有效且安全地预防和治疗心包炎。

OBJECTIVE： To systematically evaluate the efficacy and safety of colchicine for the prevention and treatment of pericarditis. METHODS： Retrieved from OVID, EMbase, SCI, CBM, CNKI, VIP, randomized controlled trials（RCTs）of colchi- cine for the prevention and treatment of pericarditis were included. Meta-analysis were carried out for homogeneity study using Rev- Man 5.0 software after systematical study selection, data extraction and quality evaluation. RESULTS： 5 RCTs were included, in- volving 795 patients. Meta-analysis indicated the differences of the incidence of the PPS[RR：0.44,95 % CI（0.27,0.70）, P= 0.000 6] and the recurrence rate [RR=0.42,95%CI（0.29,0.60）,P〈0.000 1] between groups were significant. There was no significant dif- ference in the incidence of ADRs between 2 groups [RR=1.22, 95%CI（0.72, 2.07）, P=0.47]. CONCLUSION： Based on routine treatment or routine treatment combined with aspirin, colchicine is safe and effective in the prevention and treatment of pericarditis.